The FDA is requiring Eli Lilly to conduct extensive postmarketing studies for its newly approved GLP-1 pill Foundayo (orforglipron) to further assess potential safety risks.
The agency said additional data is needed to evaluate risks, including major adverse cardiovascular events, drug-induced liver injury and medullary thyroid cancer, as well as delayed gastric emptying associated with the therapy, according to an April 1 letter.
The approval includes multiple required studies and registries, including long-term monitoring of thyroid cancer risk for at least 15 years and a 10-year pediatric registry assessing growth, development and adverse events in patients treated for obesity.
Lilly must also complete pediatric trials, including a 72-week study in patients ages 12-17 and an 84-week study in patients ages 6-11, along with additional studies tracking pregnancy exposure and long-term outcomes.
The FDA approved Foundayo for adults with obesity or overweight with weight-related conditions based on data submitted Jan. 20, but said ongoing studies are needed to better define the drug’s long-term safety profile.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
